Deakin Health Economics, Deakin University, Burwood, Victoria, Australia.
Acad Pediatr. 2012 May-Jun;12(3):171-80. doi: 10.1016/j.acap.2012.02.002.
Universal newborn hearing screening for bilateral permanent congenital hearing impairment is standard practice in many developed economies, but until there is clear evidence of cost-effectiveness, it remains a controversial use of limited health care resources. We conducted a formal systematic review of studies of newborn hearing screening that considered both costs and outcomes to produce a summary of the available evidence and to determine whether there was a need for further research.
A search was conducted of medical and nursing databases and gray literature websites by the use of multiple keywords. The titles and abstracts of studies were examined for preliminary inclusion if reference was made to newborn hearing screening, and to both costs and outcomes. Studies of potential relevance were independently assessed by 2 health economists for final inclusion in the review. Studies that met inclusion criteria were appraised by the use of existing guidelines for observational studies, economic evaluations and decision analytic models, and reported in a narrative literature review.
There were 22 distinct observational or modeled evaluations of which only 2 clearly compared universal newborn hearing screening to risk factor screening for bilateral permanent congenital hearing impairment. Of these, the single evaluation that examined long-term costs and outcomes found that universal newborn hearing screening could be cost-saving if early intervention led to a substantial reduction in future treatment costs and productivity losses.
There are only a small number of economic evaluations that have examined the long-term cost-effectiveness of universal newborn hearing screening. This is partly attributable to ongoing uncertainty about the benefits gained from the early detection and treatment of bilateral permanent congenital hearing impairment. There is a clear need for further research on long-term costs and outcomes to establish the cost-effectiveness of universal newborn hearing screening in relation to other approaches to screening, and to establish whether it is a good long term investment.
在许多发达经济体中,对双侧永久性先天性听力障碍的新生儿进行普遍听力筛查是标准做法,但在有明确成本效益证据之前,这仍然是对有限医疗资源的有争议的使用。我们对同时考虑成本和结果的新生儿听力筛查研究进行了正式的系统评价,以总结现有证据,并确定是否需要进一步研究。
使用多个关键词对医学和护理数据库以及灰色文献网站进行了搜索。如果研究提到了新生儿听力筛查以及成本和结果,则会对其标题和摘要进行初步纳入检查。有潜在相关性的研究由 2 位健康经济学家独立评估,以最终纳入审查。符合纳入标准的研究使用现有的观察性研究、经济评估和决策分析模型指南进行评估,并以叙述性文献综述的形式报告。
共有 22 项不同的观察性或建模评估,其中只有 2 项明确将普遍新生儿听力筛查与双侧永久性先天性听力障碍的风险因素筛查进行了比较。在这些评估中,唯一一项检查长期成本和结果的评估发现,如果早期干预导致未来治疗成本和生产力损失大幅减少,普遍新生儿听力筛查可能具有成本效益。
只有少数经济评估研究了普遍新生儿听力筛查的长期成本效益。这在一定程度上归因于从早期发现和治疗双侧永久性先天性听力障碍中获得的益处仍存在不确定性。需要进一步研究长期成本和结果,以确定普遍新生儿听力筛查相对于其他筛查方法的成本效益,并确定其是否是一项良好的长期投资。